The Bayh-Dole Act: A 2026 Plain-Language Guide

The Bayh-Dole Act Explained: How University Inventions Become Commercial Products

The Bayh-Dole Act of 1980 is the single most important law shaping how research funded by the US government becomes commercial products. It is the legal foundation of the modern university tech transfer system, the reason every major research university has an Office of Technology Licensing, and the framework that has produced everything from the Google search algorithm to mRNA vaccine platforms.

It is also one of the most misunderstood pieces of legislation in US science policy. This guide explains what Bayh-Dole actually does, what it requires of universities, the long-dormant march-in debate that has resurfaced in recent years, and what every researcher, TTO professional, and policy observer should understand about how it works.

Key Takeaways

• The Bayh-Dole Act (1980) lets universities, nonprofits, and small businesses retain title to inventions arising from federally funded research, in exchange for specific disclosure, patenting, and royalty-sharing obligations.
• Before 1980, fewer than 5 percent of the roughly 28,000 federally held patents had been licensed for commercial use. The Act unlocked decades of basic research for commercialization.
• The federal government keeps two rights: a non-exclusive royalty-free license for government use, and "march-in rights" that allow it to compel additional licensing under defined conditions.
• March-in rights have been petitioned multiple times since 1980, including in drug-pricing cases. They have never been exercised.
• Universities typically share 30-50 percent of net licensing income with named inventors. The institution's share is restricted to research, education, and tech-transfer operations.

What is the Bayh-Dole Act, in one paragraph?

The Bayh-Dole Act, officially the Patent and Trademark Law Amendments Act of 1980, gave universities, nonprofits, and small businesses the right to retain ownership of inventions arising from federally funded research. The conditions: disclose those inventions to the funding agency, file patent applications within reasonable timeframes, give US manufacturing preference for exclusive licenses, share royalty income with inventors, and use net licensing income for research and education. In exchange, the federal government retains a non-exclusive, royalty-free license to practice the invention for government purposes, and reserves so-called march-in rights that allow it to compel additional licensing if the technology is not being made available to the public on reasonable terms.

That single paragraph contains the entire shape of US tech transfer. Everything else is implementation.

What problem did Bayh-Dole solve?

Before 1980, inventions arising from federally funded research generally belonged to the funding agency. By the late 1970s, the federal government held title to roughly 28,000 patents. Fewer than 5 percent had been licensed for commercial use.

The reason was a near-universal policy of granting only non-exclusive licenses. A company that invested years and millions of dollars to develop a federally owned invention into a marketable product had no way to prevent competitors from licensing the same patent and free-riding on the investment. Without exclusivity, no company would commit the capital. The patents sat unused.

The cost was not abstract. Promising medical technologies, materials, and industrial processes funded by federal dollars never reached the market because the legal structure made commercialization economically irrational. The same research labs were producing world-class science whose downstream economic and human benefits were being quietly squandered.

How did the law get passed?

The law is named for Senators Birch Bayh (D-Indiana) and Bob Dole (R-Kansas), who co-sponsored the legislation in 1978 and pushed it through Congress over significant resistance. The political coalition was unusual: Democratic Senator Bayh and Republican Senator Dole, supported by a coalition of university administrators, small-business advocates, and policy researchers who had documented the commercialization gap.

The Act passed in December 1980 and took effect on July 1, 1981. Subsequent amendments, most notably in 1984 and 2000, refined definitions, expanded coverage, and clarified compliance procedures, but the core framework has remained intact for more than four decades.

The downstream effects are well documented. US university patenting activity expanded dramatically after 1980. University-industry research partnerships grew. Startup formation from research labs became a recognized commercialization path. The Association of University Technology Managers (AUTM), which conducts an annual licensing survey, has tracked tens of billions of dollars in cumulative licensing revenue and tens of thousands of startups founded on university IP since the law took effect.

What does the law actually require?

Bayh-Dole's requirements fall into five categories. A university (or other covered entity) that wants to retain title to a federally funded invention must do the following.

Disclose the invention to the funding agency. Within a defined period, typically two months from the time the inventor reports the invention to the institution, the institution must notify the federal agency that funded the research. This is the trigger event for everything that follows. Late or missing disclosure is the most common Bayh-Dole compliance failure.

Elect to retain title within statutory deadlines. The institution has a defined window (typically two years from disclosure to the agency) to formally elect to retain title to the invention. If it does not elect, title can revert to the funding agency, which may then dispose of the invention itself.

File patent applications within reasonable timeframes. Once title is elected, the institution must pursue patent protection within timeframes specified by the funding agency's implementing regulations. Failure to file removes the institution's right to retain title.

Give US manufacturing preference for exclusive licenses. Any exclusive license to a product to be sold in the United States must, where practical, require that the product be substantially manufactured in the US. This requirement can be waived by the funding agency, and waivers are common in industries where US manufacturing capacity is limited.

Share royalty income with inventors. The law does not prescribe a specific percentage, but it requires the institution to share a portion of net royalty income with the inventors. In practice, US universities typically share 30-50 percent of net income with named inventors. The remainder funds further research, the TTO's operating costs, and the university's general fund.

In addition, the institution must use net licensing income for research, education, and tech-transfer operations, not for unrelated purposes, and must submit periodic reports to the funding agency on the status of patent applications and commercialization activity.

What does the federal government keep?

In exchange for letting institutions retain title, the federal government keeps two important rights.

A non-exclusive, royalty-free license for government use. The funding agency can practice the invention itself, or have it practiced on its behalf, for any government purpose. In practice this is rarely exercised, since the federal government is not usually a direct user of university inventions, but the right is permanent and worldwide.

March-in rights. Under section 203 of the Act, the funding agency may require the institution or its exclusive licensee to grant a license to another applicant on reasonable terms (or grant such a license itself) under any of four specific conditions: (1) the institution or licensee has not taken effective steps to achieve practical application of the invention; (2) action is necessary to alleviate health or safety needs not reasonably satisfied by the institution or licensee; (3) action is necessary to meet requirements for public use specified by federal regulations; or (4) the US manufacturing preference has been breached.

March-in rights are the most-discussed and least-exercised feature of Bayh-Dole.

What is the march-in rights debate?

March-in rights have been formally petitioned multiple times since 1980, in cases involving high-priced AIDS drugs, glaucoma treatments, prostate cancer therapies, and most recently the prostate cancer drug Xtandi. They have never been exercised. Every petition has either been denied, dropped, or rendered moot by other developments.

The policy debate around march-in rights has intensified in recent years, particularly in connection with pharmaceutical pricing. Advocates argue that drugs developed with substantial federal research funding but sold at prices that put them out of reach for many Americans fail Bayh-Dole's implicit standard of making the technology available to the public on reasonable terms. Critics, including some of Bayh-Dole's original drafters, argue that the law's march-in provisions were never intended as a price-control mechanism, and that triggering them on pricing grounds would chill the private investment the law was specifically designed to attract.

Recent administrations have proposed updated guidance on march-in rights. The legal and policy debate continues. For TTOs and licensees operating under Bayh-Dole today, the practical reality remains unchanged: march-in rights have never been used, and licensing agreements continue to be drafted on the assumption that they probably won't be. But the political conversation around them is now louder than it has been at any point since the Act was passed.

Who is covered by Bayh-Dole?

Bayh-Dole's original coverage was narrow, limited to small businesses and nonprofit organizations (including universities) receiving federal R&D funding. A presidential memorandum in 1983 extended the same framework to large businesses by executive order, and subsequent legislation cemented that extension.

Today the framework covers:

• Universities and nonprofits performing federally funded research
• Small businesses receiving federal R&D contracts or grants (including under the SBIR/STTR programs)
• Large businesses operating under federal R&D contracts
• Federal contractors generally, including national-lab management contractors

It does not cover inventions made outside federal funding, inventions made by federal employees in their official capacity (those are handled under a separate framework), or inventions assigned to the government by other means.

How does royalty money actually flow?

Once a university generates licensing income from a Bayh-Dole-covered invention, the money flows through a defined allocation. The specifics vary by institution, but a typical structure looks like this.

First, direct expenses are recovered: outside patent counsel costs, filing fees, maintenance fees, and any deal-specific legal expenses. Second, the remaining net royalty income is divided three ways. Named inventors typically receive 30-50 percent. The inventor's department or lab receives 10-20 percent. The university's general research fund receives the remainder, which also funds the TTO's operations.

The institution's share is restricted by Bayh-Dole to research, education, and the operation of the tech-transfer function. It cannot be used for unrelated institutional purposes.

The inventor share is meaningful. For a license generating $1 million per year in net royalties, a 35 percent inventor share is $350,000 per year. That's substantial for the inventor and a powerful behavioral incentive for faculty to disclose inventions and engage with the TTO. The 30-50 percent range is wider than most people realize: top universities have actively used inventor-share rates as a competitive tool for faculty recruitment.

How does Bayh-Dole compare to similar laws elsewhere?

The Bayh-Dole framework has been widely studied and partially copied around the world. The most direct analogs:

• United Kingdom. Universities in the UK retain title to inventions under their own institutional policies. There is no single statute equivalent to Bayh-Dole, but the operational outcome is similar.
• Germany. The 2002 Employee Inventions Act gave universities title to inventions made by employees, replacing an earlier system in which professors owned their own inventions individually (the so-called Hochschullehrerprivileg).
• Japan. The 1999 Law to Promote Technology Transfer from Universities and the broader Technology Transfer Promotion Law established a Bayh-Dole-style framework for Japanese national universities.
• China. The 2007 Science and Technology Progress Law contains provisions modeled in part on Bayh-Dole, though implementation varies by institution.

The comparisons are useful but imperfect. National research-funding structures, patent systems, and university-industry relationships differ enough that the Bayh-Dole model does not transplant cleanly. The general direction, giving universities title to publicly funded inventions in exchange for commercialization obligations, has become the global default for high-research-activity economies.

What are common compliance pitfalls?

In thirty years of Bayh-Dole operations, certain compliance failures recur. The most common are listed below.

Late invention disclosure to the funding agency. The two-month clock from inventor disclosure to agency notification is short, and disclosures that arrive late expose the institution to losing title. TTOs that automate the agency-notification step through their case management software dramatically reduce this risk.

Missed election deadline. The window to elect title is generous, but it ends. Inventions that sit in unresolved triage past the deadline can revert to the funding agency.

Inadequate inventor share documentation. When inventor share is later disputed, usually after a license starts generating substantial revenue, the absence of clear written records of the share allocation, contributor identification, and inventor signatures is the most common source of internal conflict.

Manufacturing-preference oversights. Exclusive licenses to products sold in the US must include a US-manufacturing requirement unless a waiver has been obtained. Standard license templates that omit this clause create technical violations that surface during audits.

Reporting gaps. Periodic reports to funding agencies on the status of patent applications and commercialization activity are easy to defer in the day-to-day pressure of running a TTO. Compliance audits routinely surface multi-year reporting gaps.

None of these are catastrophic in isolation, but they accumulate. A funding agency that finds repeated late disclosures, missed deadlines, or reporting gaps may invoke its rights to take title to specific inventions or, in extreme cases, to all inventions arising from a particular grant.

What does Bayh-Dole mean for researchers?

If you are a researcher at a US university or research institution receiving federal funding, three practical implications matter most.

1. You almost certainly do not own your inventions. Under your employment agreement and Bayh-Dole, inventions made using university resources or federal funding belong to the institution. The legal structure assumes this.

2. You are required to disclose. The Act, your employment contract, and Federal Acquisition Regulations all require timely invention disclosure. Skipping disclosure is a contractual breach with legal consequences, not a personal choice.

3. You will share in revenue. Bayh-Dole and university policy guarantee inventors a share of net licensing income, usually 30-50 percent. For successful inventions, this can be substantial.

For most researchers, the practical message is straightforward: disclose early, work with your TTO, and the Act's framework will usually serve your interests as well as the institution's.

What does Bayh-Dole mean for industry?

For companies licensing university technology, Bayh-Dole shapes several specific provisions you will encounter in every license agreement:

• Federal funding clauses acknowledging that the technology arose from federally funded research and confirming the federal government's retained rights.
• US manufacturing preference clauses in any exclusive license to products sold in the US.
• Reporting and milestone obligations flowing from the institution's reporting obligations under Bayh-Dole.
• March-in acknowledgment in some agreements, though many do not address it explicitly.

These clauses are non-negotiable in their substance. A potential licensee that pushes for their removal will be told (correctly) that the university has no authority to waive Bayh-Dole obligations. The clauses can be refined and clarified, but not eliminated.

Frequently asked questions

Is the Bayh-Dole Act still in effect?

Yes. Bayh-Dole is in effect and has been amended several times since 1980, most recently in technical updates over the past two decades. The core framework is unchanged.

Can a university opt out of Bayh-Dole?

A university can decline to elect title to a specific invention, in which case title reverts to the funding agency. It cannot opt out of the framework wholesale while continuing to accept federal research funding.

Do inventors get to choose how their invention is licensed?

Not directly. Once an invention is disclosed and the university elects title, licensing decisions are the institution's. Most TTOs consult inventors closely during licensing negotiations, both because inventor cooperation is operationally helpful and because policies often require inventor sign-off, but the legal authority is the university's.

Has the federal government ever exercised march-in rights?

No. Multiple petitions have been filed since 1980, particularly in pharmaceutical pricing cases. All have been denied or rendered moot. The policy debate continues.

What is the difference between Bayh-Dole and patent law generally?

Patent law governs whether an invention is patentable and what rights a patent confers. Bayh-Dole governs ownership of inventions made with federal research funding. The two operate in parallel: an invention can be patentable but uncovered by Bayh-Dole (if no federal funding was used), or covered by Bayh-Dole but unpatentable.

Does Bayh-Dole apply to software?

Yes, where the software is patentable subject matter. It also applies to copyrighted works under certain conditions and to other intellectual property assets arising from federally funded research.

How does Bayh-Dole interact with SBIR/STTR programs?

SBIR (Small Business Innovation Research) and STTR (Small Business Technology Transfer) awards are federal R&D funding, so inventions arising from them fall under Bayh-Dole's framework. Small businesses receiving SBIR/STTR funding can retain title to their inventions under the same Bayh-Dole conditions that apply to universities.

What happens if a university does not file a patent on a disclosed invention?

If the institution chooses not to file, title to the invention can be requested by the funding agency. If the agency also does not file, the inventors may, in some circumstances, request title to the invention themselves. The specific procedure varies by funding agency.

Are foreign-funded inventions covered?

No. Bayh-Dole specifically covers inventions arising from US federal research funding. Inventions funded by foreign governments, private foundations, or industry sponsors are governed by the relevant funding agreement, not by Bayh-Dole.

Related reading

The Bayh-Dole framework is the legal foundation. The operational workflow built on top of it is the tech transfer process. If you are working in or with a TTO, the pillar guide walks through how Bayh-Dole obligations become day-to-day practice across the ten-stage workflow.

Adjacent reading:

• How to License University Technology, the licensee's view of the workflow Bayh-Dole creates.
• The Complete Guide to Licensing University IP in 2026, commercial-side licensing strategy.
• Why University Innovations Die in the Lab, the structural reasons most Bayh-Dole-covered inventions never reach market.
• SBIR/STTR Complete Guide, federal small-business research funding programs that operate under Bayh-Dole.
• University Tech Commercialization: 30 Years of Lessons, what the data shows about Bayh-Dole's track record.